Abcam, ab217298, ABT-199 (Venetoclax), Bcl-2 inhibitor.

Size: 1mg / 5mg
MW 868.4 Da, Purity >98%. Potent, selective Bcl-2 inhibitor (K i <0.01 nM) that inhibits the growth of Bcl-2–dependent tumors while sparing platelets. Bcl-2–specific BH3 mimetic. Promising agent in the treatment of chronic lymphocytic leukaemic and estrogen receptor-positive breast cancer.
Key facts
CAS number:1257044-40-8,
Purity:>98%,
Form:SolidSee storage information,
Molecular weight:868.4 Da,
Molecular formula:C45H50ClN7O7S,
PubChem:49846579,
Nature:Synthetic,
Solubility:Soluble in DMSO to 50 mM,
Biochemical name:Venetoclax,
Biological description:Potent, selective Bcl-2 inhibitor (Ki <0.01 nM) that inhibits the growth of Bcl-2–dependent tumors while sparing platelets. Bcl-2–specific BH3 mimetic. Promising agent in the treatment of chronic lymphocytic leukaemic and estrogen receptor-positive breast cancer.,
Canonical smiles:CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C,
InChi:InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54),
InChiKey:LQBVNQSMGBZMKD-UHFFFAOYSA-N,
IUPAC Name:4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide

Product details:
This product is manufactured by BioVision, an Abcam company and was previously called 2253 BCl-2 Inhibitor, ABT-199. 2253-5 is the same size as the 5 mg size of ab217298.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C, Storage information-Store under desiccating conditions

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Bcl-2 Bcl-XL and Bcl2L2 are members of the Bcl-2 protein family known for their roles in regulating apoptosis through mitochondrial membrane integrity. Bcl-2 also known as B-cell lymphoma 2 has a mass of around 26 kDa and is expressed in several tissues including the lymphatic system brain and reproductive organs. Bcl-XL is similarly pivotal in the cellular life cycle whereas Bcl2L2 also called Bcl-w shares overlapping functions. These proteins primarily localize to the outer mitochondrial membrane where they control the release of apoptogenic factors.
Biological function summary
The Bcl-2 family proteins regulate programmed cell death by either promoting or inhibiting apoptosis. As anti-apoptotic members of this family Bcl-2 Bcl-XL and Bcl2L2 bind to pro-apoptotic proteins preventing them from forming pores in the mitochondrial membrane. They are part of a complex dynamic with other Bcl-2 family proteins balancing cell survival and death. These interactions impact cell proliferation differentiation and survival under stress conditions influencing normal development and immune responses.
Pathways
The Bcl-2 family proteins act within the intrinsic apoptotic pathway which centers on mitochondrial regulation. They modulate the pathway by interacting with pro-apoptotic proteins like Bax and Bak which facilitate mitochondrial outer membrane permeabilization. This pathway plays a role in cellular responses to DNA damage and cytokine signaling connecting to broader cellular mechanisms like the stress response pathway. Their anti-apoptotic action allows cells to survive despite internal cues for programmed death contributing to tissue homeostasis.
Defects in Bcl-2 Bcl-XL and Bcl2L2 proteins relate closely to cancer and autoimmunity. Overexpression of Bcl-2 for example ties to several cancers including lymphoma where it prevents apoptosis of malignant cells. Bcl-XL also shares an association with cancer playing a role in chemoresistance. These proteins have therapeutic interest; inhibitors like venetoclax (ABT-199 GDC0199) specifically target Bcl-2 interactions to induce apoptosis in cancer cells illustrating their medical significance.